新闻源 财富源

2019年10月16日 星期三

誉衡药业(002437)公告正文

誉衡药业:2017年第三季度报告全文

公告日期:2017-10-28

  哈尔滨誉衡药业股份有限公司



证券代码:002437                证券简称:誉衡药业     公告编号:2017-123




                          哈尔滨誉衡药业股份有限公司

                               2017 年第三季度报告




                                  2017 年 10 月




                                       第1页
   哈尔滨誉衡药业股份有限公司




                                        第一节 重要提示

    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈
述或者重大遗漏,并承担个别和连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人朱吉满、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)纪作哲声明:保证季度报告中财务报
表的真实、准确、完整。




                                                   第2页
   哈尔滨誉衡药业股份有限公司




                                       第二节 公司基本情况

一、主要会计数据和财务指标

公司是否需追溯调整或重述以前年度会计数据
□ 是 √ 否

                                           本报告期末                     上年度末            本报告期末比上年度末增减

总资产(元)                                  9,095,633,259.68             8,666,544,466.23                          4.95%

归属于上市公司股东的净资产(元)              4,132,009,375.45             3,963,091,331.06                          4.26%

                                                        本报告期比上年同期                                 年初至报告期末
                                       本报告期                                      年初至报告期末
                                                                 增减                                      比上年同期增减

营业收入(元)                         724,034,736.10                    -1.41%         1,989,201,845.68             -4.86%

归属于上市公司股东的净利润(元)        67,915,833.78                   -68.56%          287,079,451.90             -49.64%

归属于上市公司股东的扣除非经常性
                                        64,954,330.34                   -65.19%          283,687,516.18             -45.46%
损益的净利润(元)

经营活动产生的现金流量净额(元)       185,133,586.19                   66.13%           465,392,353.07             -18.76%

基本每股收益(元/股)                         0.0309                    -68.57%                   0.1306            -49.63%

稀释每股收益(元/股)                         0.0309                    -68.57%                   0.1306            -49.63%

加权平均净资产收益率                           1.66%                     -4.62%                   7.05%              -8.76%

截止披露前一交易日的公司总股本:

截止披露前一交易日的公司总股本(股)                                                                         2,198,122,950

                                                          本报告期                             年初至报告期末

用最新股本计算的全面摊薄每股收益(元/股)                                   0.0309                                   0.1306

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                                    单位:元

                                项目                                     年初至报告期期末金额                说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                                -1,965,442.91

计入当期损益的政府补助(与企业业务密切相关,按照国家统一标准定
                                                                                      4,997,721.80
额或定量享受的政府补助除外)

除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资
产、交易性金融负债产生的公允价值变动损益,以及处置交易性金融资                        4,515,151.35 主要系银行理财收益
产、交易性金融负债和可供出售金融资产取得的投资收益

                                                                                                      主要系经济赔偿款和
除上述各项之外的其他营业外收入和支出                                                  -3,758,641.73
                                                                                                      合同滞纳金



                                                        第3页
     哈尔滨誉衡药业股份有限公司


减:所得税影响额                                                                       424,631.45

      少数股东权益影响额(税后)                                                       -27,778.66

合计                                                                                 3,391,935.72          --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                                单位:股

                                                            报告期末表决权恢复的优先
报告期末普通股股东总数                             43,244                                                              0
                                                            股股东总数(如有)

                                                前 10 名股东持股情况

                                                                                  持有有限售条      质押或冻结情况
               股东名称                 股东性质       持股比例      持股数量
                                                                                  件的股份数量 股份状态         数量

哈尔滨誉衡集团有限公司               境内非国有法人         42.63% 937,125,000                0 质押       862,008,386

YU HENG INTERNATIONAL
                                     境外法人               19.54% 429,578,904                0 质押       339,373,600
INVESTMENTS CORPORATION

ORIENTAL KEYSTONE INVESTMENT
                                     境外法人                1.95%   42,904,599               0
LIMITED

云南国际信托有限公司-盛锦 16 号集
                                     其他                    1.53%   33,627,939               0
合资金信托计划

陕西省国际信托股份有限公司-陕国
投荣耀 14 号证券投资集合资金信托计 其他                      1.09%   24,010,534               0


杨红冰                               境内自然人              0.89%   19,605,000      14,703,750

中央汇金资产管理有限责任公司         国有法人                0.72%   15,767,700               0

张浩                                 境内自然人              0.71%   15,699,395               0

云南国际信托有限公司-盛锦 15 号集
                                     其他                    0.71%   15,677,687               0
合资金信托计划

宋克利                               境内自然人              0.47%   10,426,303               0

                                        前 10 名无限售条件股东持股情况

                       股东名称                             持有无限售条件股份数量                  股份种类



                                                       第4页
   哈尔滨誉衡药业股份有限公司


                                                                                     股份种类          数量

哈尔滨誉衡集团有限公司                                                 937,125,000 人民币普通股       937,125,000

YU HENG INTERNATIONAL INVESTMENTS
                                                                       429,578,904 人民币普通股       429,578,904
CORPORATION

ORIENTAL KEYSTONE INVESTMENT LIMITED                                    42,904,599 人民币普通股        42,904,599

云南国际信托有限公司-盛锦 16 号集合资金信托计划                        33,627,939 人民币普通股        33,627,939

陕西省国际信托股份有限公司-陕国投荣耀 14 号证券投
                                                                        24,010,534 人民币普通股        24,010,534
资集合资金信托计划

中央汇金资产管理有限责任公司                                            15,767,700 人民币普通股        15,767,700

张浩                                                                    15,699,395 人民币普通股        15,699,395

云南国际信托有限公司-盛锦 15 号集合资金信托计划                        15,677,687 人民币普通股        15,677,687

宋克利                                                                  10,426,303 人民币普通股        10,426,303

韦秀萍                                                                  10,340,451 人民币普通股        10,340,451

                                                     1、哈尔滨誉衡集团有限公司、YU HENG INTERNATIONAL
                                                     INVESTMENTS CORPORATION 以及 ORIENTAL KEYSTONE
                                                     INVESTMENT LIMITED 由同一实际控制人朱吉满控制。
上述股东关联关系或一致行动的说明                     2、实际控制人朱吉满通过《云南国际信托有限公司-盛锦 16 号
                                                     集合资金信托计划》持有公司 33,627,939 股股票。
                                                     3、未知其他股东是否存在关联关系,也未知是否属于《上市公
                                                     司收购管理办法》中规定的一致行动人。

                                                     1、张浩通过融资融券业务持有公司股票 15,699,395 股。
前 10 名普通股股东参与融资融券业务情况说明(如有)
                                                     2、宋克利通过融资融券业务持有公司股票 10,426,303 股。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                     第5页
   哈尔滨誉衡药业股份有限公司




                                                 第三节 重要事项

一、报告期主要财务数据、财务指标发生变动的情况及原因

√ 适用 □ 不适用
1、2017年9月30日资产负债表项目

      项目            期末余额         期初余额       变动率                              原因说明
应收票据            33,216,253.75    69,128,950.47    -51.95% 主要系本期银行承兑汇票到期承兑或背书转让所致
                                                                 主要系受两票制等政策推进的影响,公司逐步调整现有销售渠
应收账款            268,650,099.71 174,498,329.15     53.96%
                                                                 道,信用政策相应调整所致
预付款项            108,011,487.33   79,300,527.46    36.21% 主要系本期预付款业务增加所致
应收利息             2,082,501.31     3,691,645.64    -43.59% 主要系本期收到定期存款利息所致
                                                                 主要系本期收到上年WuXi Healthcare Ventures II, L.P.(以下简
应收股利                 0.00         480,255.45      -100.00%
                                                                 称“毓承资本”)分红款所致
                                                                 主要系本期代理保证金减少以及本期收回维康医药集团有限
其他应收款          89,379,916.55    158,211,217.84   -43.51%
                                                                 公司收购意向金所致
                                                                 主要系广州誉东健康制药有限公司(以下简称“广州誉东”)
在建工程             8,061,359.15    67,010,766.05    -87.97% 固体片剂项目和山西普德药业有限公司(以下简称“普德药
                                                                 业”)109车间项目本期转固所致
                                                                 主要系本期购买广州迈特兴华制药厂有限公司(以下简称“迈
无形资产            660,530,665.11 422,975,153.55     56.16%
                                                                 特兴华”)氯化钾缓释片制药技术所致
                                                                 主要系本期增加抗PD-1单抗产品GLS-010注射液、依折麦布、
开发支出            75,894,536.22    39,316,963.56    93.03%
                                                                 氟比洛芬酯注射液等研发项目投入所致
                                                                 主要系本期对可弥补亏损、内部交易未实现利润、2016年度所
递延所得税资产      62,909,981.40    36,276,785.11    73.42%
                                                                 得税汇算清缴的纳税调整计提递延税款所致
                                                                 主要系本期向迈特兴华购买氯化钾缓释片制药技术,尚未支付
应付账款            188,205,368.20 113,051,388.80     66.48%
                                                                 第三期款项所致
应付票据            16,228,772.00    11,576,931.00    40.18% 主要系本期票据支付业务增加所致
预收款项            128,591,438.72 186,766,092.50     -31.15% 主要系本期预收货款业务减少所致
应付职工薪酬         7,385,530.69    29,967,799.26    -75.36% 主要系本期支付上年奖金所致
应付利息            35,824,989.51     3,296,268.02    986.83% 主要系本期应支付的中期票据利息和银行借款利息增加所致
应付股利             5,463,062.50    52,135,911.47    -89.52% 主要系本期支付上年末应支付的分红款所致
其他应付款          473,164,990.50 277,394,772.91     70.57% 主要系本期按照推广服务协议计提销售费用所致
                                                                 主要系本期支付普德药业、上海华拓医药科技发展有限公司
一年内到期的非
                    40,340,000.00    997,227,078.96   -95.95% (以下简称“上海华拓”)、南京万川华拓医药有限公司原股
流动负债
                                                                 东股权购买款所致
                                                                 主要系应支付普德药业原股东股权购买款转为一年内到期的
长期应付款               0.00        33,340,000.00    -100.00%
                                                                 非流动负债所致
应付债券            993,276,376.66        0.00        100.00% 主要系本期发行中期票据所致



                                                           第6页
   哈尔滨誉衡药业股份有限公司


                                                                 主要系收取的硫酸氢氯吡格雷片地区经销权买断金分期确认
其他非流动负债      6,890,073.56     10,626,916.82    -35.16%
                                                                 其他业务收入所致
其他综合收益        -3,900,968.17    4,356,921.84     -189.53% 主要系美元汇率下降导致外币报表折算差额下降所致

2、2017年1-9月利润表项目

      项目           本期发生额      上期发生额        变动率                            原因说明
                                                                 根据财会[2016]22号财政部《增值税会计处理规定》,本期主
税金及附加          37,411,951.88    26,053,025.13     43.60% 要增加了房产税、土地使用税、车船使用税、印花税在本科目
                                                                 的列示
                                                                 主要系受两票制政策推进影响,公司销售渠道市场费用增加所
销售费用            497,176,822.30 162,482,911.07 205.99%
                                                                 致
                                                                 主要系本期转让海南华拓天涯制药有限公司股权及收到毓承
投资收益             6,316,599.05    10,587,623.36    -40.34%
                                                                 资本分红所致
财务费用            123,862,723.96   75,710,298.24     63.60% 主要系本期中期票据利息增加所致
资产减值损失         6,885,698.65    3,331,649.68     106.68% 主要系应收款项坏账准备和固定资产减值准备增加所致
                                                                 主要系根据企业会计准则,将与企业日常活动相关的政府补助
其他收益             4,360,021.54        0.00         100.00%
                                                                 重分类至其他收益,上年同期不追溯调整所致
                                                                 主要系本期收到的政府补助减少及根据企业会计准则将与企
营业外收入           2,208,364.24    56,686,364.34    -96.10%
                                                                 业日常活动相关的政府补助重分类至其他收益所致
营业外支出           7,293,087.55    4,649,247.02      56.87% 主要系本期经济赔偿款和合同滞纳金增加所致
所得税费用          51,880,002.09    99,315,162.59    -47.76% 主要系利润总额下降所致
                                                                 主要系誉衡基因生物科技(深圳)有限公司、宁波誉东健康科
少数股东损益        -4,280,830.64    6,496,830.30     -165.89% 技有限公司、北京普德康利医药科技发展有限公司加大研发投
                                                                 入导致亏损增加所致

3、2017年1-9月现金流量表项目

      项目           本期发生额      上期发生额        变动率                            原因说明
筹资活动产生的
                    811,916,917.11 445,708,229.51      82.16% 主要系本期增加发行中期票据并偿还银行借款所致
现金流量净额


二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用
1、已公告的重要事项及进展情况

               重要事项概述                         披露日期                     临时报告披露网站查询索引

                                                                   详见发布在中国证监会指定信息披露媒体《中国证券报》、
下属公司广州誉东取得氯化钾缓释片的生                               《证券时报》及巨潮资讯网 http://www.cninfo.com.cn(以下
                                            2017 年 07 月 06 日
产相关资质                                                         简称“指定媒体”)的《关于下属公司广州誉东健康制药有
                                                                   限公司收购药品生产技术等无形资产的进展公告》。

                                                                   详见发布在指定媒体的《关于部分已授予但尚未解锁的限
完成部分离职人员限制性股票回购注销          2017 年 07 月 26 日
                                                                   制性股票回购注销完成的公告》。

                                                                   详见发布在指定媒体的《关于出售山西普德药业有限公司
终止出售普德药业 100%股权                   2017 年 08 月 16 日
                                                                   100%股权的进展公告》。


                                                               第7页
   哈尔滨誉衡药业股份有限公司


与药明生物技术有限公司许可美国 Arcus
                                                                 详见发布在指定媒体的《关于与药明生物技术有限公司许
Biosciences,Inc.在北美、日本、欧洲等区域
                                           2017 年 08 月 18 日 可美国 Arcus Biosciences,Inc.在境外特定区域独家开发、商
独家开发、商业化抗 PD-1 全人创新抗体药
                                                                 业化抗 PD-1 全人创新抗体药的公告》。
GLS-010 注射液

                                                                 详见发布在指定媒体的《2017 年第五次临时股东大会决议
完成第四届董事会、监事会成员选举           2017 年 09 月 12 日
                                                                 公告》、《关于选举第四届监事会职工代表监事的公告》。

                                                                 详见发布在指定媒体的《关于终止全资子公司上海华拓医
终止全资子公司上海华拓财务融资及解除
                                           2017 年 09 月 29 日 药科技发展有限公司财务融资及解除对本次财务融资相应
对本次财务融资相应担保
                                                                 担保的公告》。

2、其他事项
⑴ 2017 年 9 月,中国医药工业信息中心主办的 2017 年(第 34 届)全国医药工业信息年会发布了工信部 2016 年度中国医
药工业百强企业榜单。继 2015 年度后,公司再次获得该殊荣。
⑵ 2017 年 9 月,公司荣获首届黑龙江省人民政府质量奖提名奖。
⑶ 2017 年 9 月,公司与国药控股股份有限公司(以下简称“国药控股”)正式签署战略合作协议,确立了“工商携手、共
创未来”的集团化战略发展合作模式。公司产品在国药控股体系内将享受战略合作伙伴商务政策,终端的合作开发和基于大
数据的信息化共享等合作也将再上一个台阶。
⑷ 2017 年 8 月,2017“健康中国品牌榜”系列榜单在西普会上发布,公司产品葡萄糖酸钙锌口服溶液荣登儿童维生素矿
物质补充用药品类品牌榜,连续两年上榜;2017 年 10 月,“第十七届中国药店高峰论坛暨《中国药店》杂志创刊十七周年
盛典”揭晓了中国药店 30 个不同品类店员推荐率最高的品牌产品,葡萄糖酸钙锌口服溶液再一次从上万 OTC 品牌中脱颖而
出,被评选为“2017 年度中国药店店员推荐率最高品牌”。继 2015-2016 年蝉联此项殊荣之后,已经连续三年登榜!


三、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行
完毕的承诺事项

√ 适用 □ 不适用

     承诺事由        承诺方      承诺类型                        承诺内容              承诺时间 承诺期限    履行情况

                                                承诺其持有权益达 50%以上或实际控
                                                制的企业或单位("附属公司")目前并
                                                没有直接或间接地从事任何与公司实
                                                际从事的业务发生利益冲突或在市
                                                场、资源、地域方面存在竞争的任何
                                                业务活动。其及其附属公司在今后的
                    哈尔滨誉 关于同业竞争、关 任何时间不会直接或间接地以任何方
                                                                            2010 年 06
首次公开发行或再 衡集团有 联交易、资金占用 式(包括但不限于自营、合资或联营)            长期                正常履行中
                                                                            月 23 日
融资时所作承诺   限公司   方面的承诺       参与或进行与公司实际从事的业务存
                                                在直接或间接竞争的任何业务活动
                                                (与公司合作开发除外)。凡其及其附属
                                                公司有任何商业机会可从事、参与或
                                                入股任何可能会与公司生产经营构成
                                                竞争的业务,会将上述商业机会优先
                                                让予公司。

                    朱吉满、 关于同业竞争、关 承诺其及其实际控制的企业或单位(" 2010 年 06 长期             正常履行中


                                                         第8页
   哈尔滨誉衡药业股份有限公司


                   白莉惠     联交易、资金占用 附属公司")目前并没有直接或间接地 月 23 日
                              方面的承诺      从事任何与公司实际从事的业务发生
                                              利益冲突或在市场、资源、地域方面
                                              存在竞争的任何业务活动。其及其附
                                              属公司在今后的任何时间不会直接或
                                              间接地以任何方式(包括但不限于自
                                              营、合资或联营)参与或进行与公司实
                                              际从事的业务存在直接或间接竞争的
                                              任何业务活动(与公司合作开发除外)。
                                              其及其附属公司有任何商业机会可从
                                              事、参与或入股任何可能会与公司生
                                              产经营构成竞争的业务,会将上述商
                                              业机会优先让予公司。

                                              限售期届满后,在担任公司董事、监
                   朱吉满、
                                              事或高管人员期间,每年转让的股份
                   白莉惠、                                                       2010 年 06
                              股份限售承诺    不超过所间接持有公司股份总数的                   长期      正常履行中
                   王东绪、                                                       月 23 日
                                              25%;离职后半年内,不转让所间接
                   杨红冰
                                              持有的公司股份。

                                              限制性股票激励计划授予对象朱吉满
                                                                                  2014 年 10
股权激励承诺       朱吉满     股份限售承诺    先生承诺所获股票自授予日起三十六                 36 个月   正常履行中
                                                                                  月 31 日
                                              个月内不得转让。

承诺是否按时履行 是

如承诺超期未履行
完毕的,应当详细
说明未完成履行的 不适用。
具体原因及下一步
的工作计划


四、对 2017 年度经营业绩的预计

2017 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2017 年度归属于上市公司股东的净利润变动幅度                                 -60.00%    至                    -40.00%

2017 年度归属于上市公司股东的净利润变动区间(万元)                        28,665.93   至                   42,998.90

2016 年度归属于上市公司股东的净利润(万元)                                                                 71,664.83

                                                        1、受两票制政策推进影响,公司逐步调整现有销售渠道,降
                                                        低渠道产品库存,产品发货减少;

业绩变动的原因说明                                      2、部分产品销售受国家医保目录调整影响;
                                                        3、收到的政府补助较上年同期有所下降;
                                                        4、继续加大生物药的研发投入。




                                                      第9页
   哈尔滨誉衡药业股份有限公司


五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

□ 适用 √ 不适用
公司报告期内未发生接待调研、沟通、采访等活动。




                                                  第 10 页
   哈尔滨誉衡药业股份有限公司




                                       第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:哈尔滨誉衡药业股份有限公司
                                         2017 年 09 月 30 日
                                                                                              单位:元

                 项目                         期末余额                        期初余额

流动资产:

    货币资金                                             1,292,433,945.29           1,201,833,976.58

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据                                               33,216,253.75                 69,128,950.47

    应收账款                                              268,650,099.71             174,498,329.15

    预付款项                                              108,011,487.33                 79,300,527.46

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                                   2,082,501.31               3,691,645.64

    应收股利                                                                               480,255.45

    其他应收款                                             89,379,916.55             158,211,217.84

    买入返售金融资产

    存货                                                  347,025,968.09             271,256,152.62

    划分为持有待售的资产

    一年内到期的非流动资产                                     7,128,235.46               7,343,985.54

    其他流动资产                                           48,898,802.44                 46,643,797.62

流动资产合计                                             2,196,827,209.93           2,012,388,838.37

非流动资产:

    发放贷款及垫款



                                              第 11 页
  哈尔滨誉衡药业股份有限公司


    可供出售金融资产                             240,882,251.96     243,931,346.80

    持有至到期投资

    长期应收款

    长期股权投资                                 271,962,841.20     236,436,717.30

    投资性房地产

    固定资产                                    1,763,901,431.84   1,747,931,810.43

    在建工程                                        8,061,359.15     67,010,766.05

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                                     660,530,665.11     422,975,153.55

    开发支出                                      75,894,536.22      39,316,963.56

    商誉                                        3,685,033,137.73   3,683,213,212.81

    长期待摊费用                                  18,107,601.75      21,654,906.79

    递延所得税资产                                62,909,981.40      36,276,785.11

    其他非流动资产                               111,522,243.39     155,407,965.46

非流动资产合计                                  6,898,806,049.75   6,654,155,627.86

资产总计                                        9,095,633,259.68   8,666,544,466.23

流动负债:

    短期借款                                    1,872,000,000.00   1,750,000,000.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据                                      16,228,772.00      11,576,931.00

    应付账款                                     188,205,368.20     113,051,388.80

    预收款项                                     128,591,438.72     186,766,092.50

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                                    7,385,530.69     29,967,799.26

    应交税费                                      73,609,560.76      98,742,092.89




                                     第 12 页
  哈尔滨誉衡药业股份有限公司


    应付利息                                35,824,989.51        3,296,268.02

    应付股利                                  5,463,062.50     52,135,911.47

    其他应付款                             473,164,990.50     277,394,772.91

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    划分为持有待售的负债

    一年内到期的非流动负债                  40,340,000.00     997,227,078.96

    其他流动负债

流动负债合计                              2,840,813,712.88   3,520,158,335.81

非流动负债:

    长期借款                               964,064,168.00     972,765,985.00

    应付债券                               993,276,376.66

      其中:优先股

               永续债

    长期应付款                                                 33,340,000.00

    长期应付职工薪酬

    专项应付款                                1,605,736.58       1,953,221.25

    预计负债

    递延收益                                46,364,815.85      49,937,337.39

    递延所得税负债                          28,967,657.32      31,127,237.98

    其他非流动负债                            6,890,073.56     10,626,916.82

非流动负债合计                            2,041,168,827.97   1,099,750,698.44

负债合计                                  4,881,982,540.85   4,619,909,034.25

所有者权益:

    股本                                  2,198,122,950.00   2,198,290,350.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                               350,130,074.98     350,560,745.38

    减:库存股                                 797,410.59        1,395,480.99

    其他综合收益                             -3,900,968.17       4,356,921.84

    专项储备



                               第 13 页
   哈尔滨誉衡药业股份有限公司


    盈余公积                                                    225,179,052.79             225,179,052.79

    一般风险准备

    未分配利润                                                 1,363,275,676.44           1,186,099,742.04

归属于母公司所有者权益合计                                     4,132,009,375.45           3,963,091,331.06

    少数股东权益                                                 81,641,343.38                83,544,100.92

所有者权益合计                                                 4,213,650,718.83           4,046,635,431.98

负债和所有者权益总计                                           9,095,633,259.68           8,666,544,466.23


法定代表人:朱吉满                     主管会计工作负责人:刁秀强                 会计机构负责人:纪作哲


2、母公司资产负债表

                                                                                                   单位:元

                   项目                             期末余额                       期初余额

流动资产:

    货币资金                                                    817,695,106.70             556,315,412.05

    以公允价值计量且其变动计入当期损
益的金融资产

    衍生金融资产

    应收票据                                                                                   8,334,507.20

    应收账款                                                           8,358.00                1,508,332.40

    预付款项                                                     13,427,240.71                16,574,087.55

    应收利息                                                       1,218,299.49                3,522,645.64

    应收股利                                                                                  39,225,000.00

    其他应收款                                                 1,576,135,318.40           1,097,897,886.40

    存货                                                                                      56,776,682.05

    划分为持有待售的资产

    一年内到期的非流动资产                                         1,926,938.89                1,960,367.76

    其他流动资产                                                306,744,453.41                 4,287,036.43

流动资产合计                                                   2,717,155,715.60           1,786,401,957.48

非流动资产:

    可供出售金融资产                                             40,300,796.80                39,300,796.80

    持有至到期投资

    长期应收款

    长期股权投资                                               6,046,641,653.84           5,507,821,539.98

    投资性房地产


                                                   第 14 页
  哈尔滨誉衡药业股份有限公司


    固定资产                                       112,331,264.85     486,754,155.94

    在建工程                                          1,227,170.81       1,669,840.64

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                                        27,936,390.86      94,739,503.98

    开发支出                                        35,646,215.70      12,356,132.08

    商誉

    长期待摊费用                                      3,240,014.71       4,672,548.97

    递延所得税资产                                  24,223,297.86        7,218,458.22

    其他非流动资产                                  74,674,430.04      69,702,826.94

非流动资产合计                                    6,366,221,235.47   6,224,235,803.55

资产总计                                          9,083,376,951.07   8,010,637,761.03

流动负债:

    短期借款                                      1,272,000,000.00   1,050,000,000.00

    以公允价值计量且其变动计入当期损
益的金融负债

    衍生金融负债

    应付票据

    应付账款                                           886,129.89      27,953,750.38

    预收款项                                          5,906,033.86     73,045,537.96

    应付职工薪酬                                        81,029.07      14,956,472.34

    应交税费                                           922,606.89      10,428,572.02

    应付利息                                        35,163,124.92        2,483,663.85

    应付股利                                          5,463,062.50     39,060,911.47

    其他应付款                                    1,777,548,076.54   1,161,838,039.36

    划分为持有待售的负债

    一年内到期的非流动负债                          33,340,000.00     935,079,578.96

    其他流动负债

流动负债合计                                      3,131,310,063.67   3,314,846,526.34

非流动负债:

    长期借款                                       800,000,000.00     800,000,000.00

    应付债券                                       993,276,376.66




                                       第 15 页
   哈尔滨誉衡药业股份有限公司


      其中:优先股

               永续债

    长期应付款                                                                          33,340,000.00

    长期应付职工薪酬

    专项应付款

    预计负债

    递延收益                                                                            23,857,500.06

    递延所得税负债

    其他非流动负债

非流动负债合计                                         1,793,276,376.66                857,197,500.06

负债合计                                               4,924,586,440.33            4,172,044,026.40

所有者权益:

    股本                                               2,198,122,950.00            2,198,290,350.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                                             714,792,798.73                715,223,469.13

    减:库存股                                               797,410.59                  1,395,480.99

    其他综合收益

    专项储备

    盈余公积                                             225,179,052.79                225,179,052.79

    未分配利润                                         1,021,493,119.81                701,296,343.70

所有者权益合计                                         4,158,790,510.74            3,838,593,734.63

负债和所有者权益总计                                   9,083,376,951.07            8,010,637,761.03


法定代表人:朱吉满              主管会计工作负责人:刁秀强                 会计机构负责人:纪作哲


3、合并本报告期利润表

                                                                                             单位:元

                 项目                   本期发生额                        上期发生额

一、营业总收入                                       724,034,736.10                    734,361,228.36

    其中:营业收入                                   724,034,736.10                    734,361,228.36

           利息收入

           已赚保费

           手续费及佣金收入

                                            第 16 页
   哈尔滨誉衡药业股份有限公司


二、营业总成本                               646,618,530.59      514,879,387.21

    其中:营业成本                           184,388,812.00      295,394,461.19

           利息支出

           手续费及佣金支出

           退保金

           赔付支出净额

           提取保险合同准备金净额

           保单红利支出

           分保费用

           税金及附加                            13,236,753.45     9,457,402.36

           销售费用                          304,309,439.10       62,148,550.83

           管理费用                              96,711,511.50   122,150,176.26

           财务费用                              47,330,030.56    25,114,620.92

           资产减值损失                            641,983.98       614,175.65

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                                  1,861,366.84     6,123,700.58
列)

           其中:对联营企业和合营
企业的投资收益

         汇兑收益(损失以“-”号填
列)

         其他收益                                 1,600,007.18

三、营业利润(亏损以“-”号填列)               80,877,579.53   225,605,541.73

    加:营业外收入                                1,000,564.29    33,515,522.62

         其中:非流动资产处置利得                   -13,377.14       119,573.02

    减:营业外支出                                 840,094.61      1,271,354.78

         其中:非流动资产处置损失                  141,472.25       855,351.05

四、利润总额(亏损总额以“-”号填
                                                 81,038,049.21   257,849,709.57
列)

    减:所得税费用                               13,483,480.03    39,836,025.43

五、净利润(净亏损以“-”号填列)               67,554,569.18   218,013,684.14

    归属于母公司所有者的净利润                   67,915,833.78   216,041,965.19

    少数股东损益                                   -361,264.60     1,971,718.95

六、其他综合收益的税后净额                       -4,013,233.11



                                      第 17 页
   哈尔滨誉衡药业股份有限公司


  归属母公司所有者的其他综合收益
                                                             -4,013,233.11
的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
                                                             -4,013,233.11
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额                          -4,013,233.11

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                             63,541,336.07                       218,013,684.14

    归属于母公司所有者的综合收益
                                                             63,902,600.67                       216,041,965.19
总额

    归属于少数股东的综合收益总额                               -361,264.60                         1,971,718.95

八、每股收益:

    (一)基本每股收益                                             0.0309                               0.0983

    (二)稀释每股收益                                             0.0309                               0.0983

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


法定代表人:朱吉满                    主管会计工作负责人:刁秀强                     会计机构负责人:纪作哲


4、母公司本报告期利润表

                                                                                                       单位:元

                 项目                          本期发生额                           上期发生额


                                                  第 18 页
   哈尔滨誉衡药业股份有限公司


一、营业收入                                     48,492,431.06   126,107,546.45

    减:营业成本                                  3,472,053.77    32,892,385.51

         税金及附加                                 83,100.39      2,034,029.34

         销售费用                                  439,385.29     11,659,041.05

         管理费用                                32,413,250.49    55,666,851.10

         财务费用                                40,069,084.13    19,070,279.00

         资产减值损失                               56,536.27        -12,741.63

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                             303,560,734.58      191,387,530.22
列)

         其中:对联营企业和合营企
业的投资收益

         其他收益                                  100,000.00

二、营业利润(亏损以“-”号填列)           275,619,755.30      196,185,232.30

    加:营业外收入                                 210,554.10      1,662,898.65

         其中:非流动资产处置利得                   -13,477.14

    减:营业外支出                                        0.01          879.95

         其中:非流动资产处置损失                                       879.95

三、利润总额(亏损总额以“-”号填
                                             275,830,309.39      197,847,251.00
列)

    减:所得税费用                               -6,985,888.89     2,895,178.52

四、净利润(净亏损以“-”号填列)           282,816,198.28      194,952,072.48

五、其他综合收益的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允


                                      第 19 页
   哈尔滨誉衡药业股份有限公司


价值变动损益

          3.持有至到期投资重分类
为可供出售金融资产损益

          4.现金流量套期损益的有
效部分

          5.外币财务报表折算差额

          6.其他

六、综合收益总额                                        282,816,198.28                 194,952,072.48

七、每股收益:

    (一)基本每股收益                                          0.1287                        0.0887

    (二)稀释每股收益                                          0.1287                        0.0887


法定代表人:朱吉满                 主管会计工作负责人:刁秀强              会计机构负责人:纪作哲


5、合并年初到报告期末利润表

                                                                                             单位:元

                 项目                      本期发生额                     上期发生额

一、营业总收入                                       1,989,201,845.68              2,090,856,772.65

    其中:营业收入                                   1,989,201,845.68              2,090,856,772.65

          利息收入

          已赚保费

          手续费及佣金收入

二、营业总成本                                       1,660,115,119.61              1,477,627,538.14

    其中:营业成本                                      690,628,725.32                 857,264,585.45

          利息支出

          手续费及佣金支出

          退保金

          赔付支出净额

          提取保险合同准备金净额

          保单红利支出

          分保费用

          税金及附加                                      37,411,951.88                 26,053,025.13

          销售费用                                      497,176,822.30                 162,482,911.07

          管理费用                                      304,149,197.50                 352,785,068.57

          财务费用                                      123,862,723.96                  75,710,298.24



                                               第 20 页
   哈尔滨誉衡药业股份有限公司


             资产减值损失                         6,885,698.65     3,331,649.68

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                                  6,316,599.05    10,587,623.36
列)

         其中:对联营企业和合营企
业的投资收益

         汇兑收益(损失以“-”号填
列)

         其他收益                                 4,360,021.54

三、营业利润(亏损以“-”号填列)           339,763,346.66      623,816,857.87

    加:营业外收入                                2,208,364.24    56,686,364.34

         其中:非流动资产处置利得                  223,457.83       167,262.80

    减:营业外支出                                7,293,087.55     4,649,247.02

         其中:非流动资产处置损失                 2,188,900.74     2,973,305.93

四、利润总额(亏损总额以“-”号填
                                             334,678,623.35      675,853,975.19
列)

    减:所得税费用                               51,880,002.09    99,315,162.59

五、净利润(净亏损以“-”号填列)           282,798,621.26      576,538,812.60

    归属于母公司所有者的净利润               287,079,451.90      570,041,982.30

    少数股东损益                                 -4,280,830.64     6,496,830.30

六、其他综合收益的税后净额                       -8,257,890.01

  归属母公司所有者的其他综合收益
                                                 -8,257,890.01
的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
                                                 -8,257,890.01
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允



                                      第 21 页
   哈尔滨誉衡药业股份有限公司


价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额                            -8,257,890.01

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                             274,540,731.25                      576,538,812.60

    归属于母公司所有者的综合收益
                                                             278,821,561.89                      570,041,982.30
总额

    归属于少数股东的综合收益总额                               -4,280,830.64                       6,496,830.30

八、每股收益:

    (一)基本每股收益                                               0.1306                             0.2593

    (二)稀释每股收益                                               0.1306                             0.2593

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


法定代表人:朱吉满                      主管会计工作负责人:刁秀强                   会计机构负责人:纪作哲


6、母公司年初到报告期末利润表

                                                                                                       单位:元

                 项目                           本期发生额                          上期发生额

一、营业收入                                                 189,269,578.12                      339,633,788.70

    减:营业成本                                               41,133,762.47                      87,151,697.76

           税金及附加                                           2,520,465.57                       5,650,354.05

           销售费用                                            13,724,530.24                      28,381,713.61

           管理费用                                          113,124,833.59                      178,736,059.86

           财务费用                                          101,229,792.08                       57,353,394.38

           资产减值损失                                         2,500,829.50                        945,200.79

    加:公允价值变动收益(损失以
“-”号填列)

           投资收益(损失以“-”号填
                                                             504,050,768.74                      765,665,218.04
列)

           其中:对联营企业和合营企
业的投资收益



                                                    第 22 页
   哈尔滨誉衡药业股份有限公司


         其他收益                                               479,249.98

二、营业利润(亏损以“-”号填列)                       419,565,383.39                747,080,586.29

    加:营业外收入                                              335,975.34               2,412,194.82

         其中:非流动资产处置利得                               111,622.86

    减:营业外支出                                            1,851,881.46                 953,394.53

         其中:非流动资产处置损失                               163,799.91                  53,394.49

三、利润总额(亏损总额以“-”号填
                                                         418,049,477.27                748,539,386.58
列)

    减:所得税费用                                           -12,050,816.34             -2,010,024.31

四、净利润(净亏损以“-”号填列)                       430,100,293.61                750,549,410.89

五、其他综合收益的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

六、综合收益总额                                         430,100,293.61                750,549,410.89

七、每股收益:

    (一)基本每股收益                                              0.1957                    0.3414

    (二)稀释每股收益                                              0.1957                    0.3414


法定代表人:朱吉满                    主管会计工作负责人:刁秀强              会计机构负责人:纪作哲



                                                  第 23 页
     哈尔滨誉衡药业股份有限公司


7、合并年初到报告期末现金流量表

                                                                                      单位:元

                项目                 本期发生额                    上期发生额

一、经营活动产生的现金流量:

      销售商品、提供劳务收到的现金            2,109,619,465.93              2,281,254,352.40

      客户存款和同业存放款项净增加


      向中央银行借款净增加额

      向其他金融机构拆入资金净增加


      收到原保险合同保费取得的现金

      收到再保险业务现金净额

      保户储金及投资款净增加额

      处置以公允价值计量且其变动计
入当期损益的金融资产净增加额

      收取利息、手续费及佣金的现金

      拆入资金净增加额

      回购业务资金净增加额

      收到的税费返还

      收到其他与经营活动有关的现金                149,687,736.92                551,590,521.45

经营活动现金流入小计                          2,259,307,202.85              2,832,844,873.85

      购买商品、接受劳务支付的现金                708,240,849.04                950,715,009.05

      客户贷款及垫款净增加额

      存放中央银行和同业款项净增加


      支付原保险合同赔付款项的现金

      支付利息、手续费及佣金的现金

      支付保单红利的现金

      支付给职工以及为职工支付的现
                                                  295,268,551.10                247,720,493.13


      支付的各项税费                              371,368,635.36                373,422,359.11

      支付其他与经营活动有关的现金                419,036,814.28                688,113,769.32

经营活动现金流出小计                          1,793,914,849.78              2,259,971,630.61

经营活动产生的现金流量净额                        465,392,353.07                572,873,243.24

二、投资活动产生的现金流量:


                                        第 24 页
  哈尔滨誉衡药业股份有限公司


    收回投资收到的现金                   2,280,825,493.65     3,507,818,013.54

    取得投资收益收到的现金                     6,121,729.88       3,771,679.89

    处置固定资产、无形资产和其他
                                               1,740,637.51         576,544.01
长期资产收回的现金净额

    处置子公司及其他营业单位收到
                                                                 28,693,020.11
的现金净额

    收到其他与投资活动有关的现金                     10.00       75,000,000.00

投资活动现金流入小计                     2,288,687,871.04     3,615,859,257.55

    购建固定资产、无形资产和其他
                                          143,885,328.79        125,965,785.37
长期资产支付的现金

    投资支付的现金                       2,349,398,063.65     3,807,778,483.54

    质押贷款净增加额

    取得子公司及其他营业单位支付
                                          997,486,881.05      1,054,439,802.84
的现金净额

    支付其他与投资活动有关的现金              30,781,255.59               0.00

投资活动现金流出小计                     3,521,551,529.08     4,988,184,071.75

投资活动产生的现金流量净额              -1,232,863,658.04     -1,372,324,814.20

三、筹资活动产生的现金流量:

    吸收投资收到的现金                         7,985,500.00      15,000,000.00

    其中:子公司吸收少数股东投资
                                               7,900,000.00      15,000,000.00
收到的现金

    取得借款收到的现金                   2,878,064,168.00     1,961,008,334.50

    发行债券收到的现金

    收到其他与筹资活动有关的现金          215,100,000.00        133,804,846.61

筹资活动现金流入小计                     3,101,149,668.00     2,109,813,181.11

    偿还债务支付的现金                   1,765,591,994.50     1,299,000,000.00

    分配股利、利润或偿付利息支付
                                          246,798,938.99        189,463,927.60
的现金

    其中:子公司支付给少数股东的
                                              13,075,000.00
股利、利润

    支付其他与筹资活动有关的现金          276,841,817.40        175,641,024.00

筹资活动现金流出小计                     2,289,232,750.89     1,664,104,951.60

筹资活动产生的现金流量净额                811,916,917.11        445,708,229.51

四、汇率变动对现金及现金等价物的
                                              -4,249,640.45               2.09
影响

五、现金及现金等价物净增加额                  40,195,971.69    -353,743,339.36



                                   第 25 页
     哈尔滨誉衡药业股份有限公司


      加:期初现金及现金等价物余额                        968,298,851.60             1,017,919,279.57

六、期末现金及现金等价物余额                           1,008,494,823.29                  664,175,940.21


法定代表人:朱吉满                   主管会计工作负责人:刁秀强              会计机构负责人:纪作哲


8、母公司年初到报告期末现金流量表

                                                                                               单位:元

                项目                         本期发生额                     上期发生额

一、经营活动产生的现金流量:

      销售商品、提供劳务收到的现金                          96,137,445.73                442,128,098.99

      收到的税费返还

      收到其他与经营活动有关的现金                     3,596,996,902.71              3,441,916,907.17

经营活动现金流入小计                                   3,693,134,348.44              3,884,045,006.16

      购买商品、接受劳务支付的现金                          34,881,487.57                 82,668,278.02

      支付给职工以及为职工支付的现
                                                            85,628,278.05                 88,098,390.83


      支付的各项税费                                        34,017,202.25                 56,646,733.90

      支付其他与经营活动有关的现金                     3,385,856,320.68              3,426,286,559.76

经营活动现金流出小计                                   3,540,383,288.55              3,653,699,962.51

经营活动产生的现金流量净额                                152,751,059.89                 230,345,043.65

二、投资活动产生的现金流量:

      收回投资收到的现金                               1,754,000,000.00              2,910,600,000.00

      取得投资收益收到的现金                              544,631,298.53                 661,708,060.57

      处置固定资产、无形资产和其他
                                                             1,021,300.00                   133,667.20
长期资产收回的现金净额

      处置子公司及其他营业单位收到
                                                                                          35,000,000.00
的现金净额

      收到其他与投资活动有关的现金                                 10.00                  75,000,000.00

投资活动现金流入小计                                   2,299,652,608.53              3,682,441,727.77

      购建固定资产、无形资产和其他
                                                            44,698,127.48                 34,003,814.97
长期资产支付的现金

      投资支付的现金                                   1,779,131,500.00              3,012,640,000.00

      取得子公司及其他营业单位支付
                                                       1,040,145,202.95              1,041,979,905.61
的现金净额

      支付其他与投资活动有关的现金                        330,000,010.00                           0.00

投资活动现金流出小计                                   3,193,974,840.43              4,088,623,720.58


                                                 第 26 页
   哈尔滨誉衡药业股份有限公司


投资活动产生的现金流量净额                             -894,322,231.90              -406,181,992.81

三、筹资活动产生的现金流量:

     吸收投资收到的现金

     取得借款收到的现金                               2,363,600,000.00             1,350,000,000.00

     发行债券收到的现金

     收到其他与筹资活动有关的现金                      195,100,000.00

筹资活动现金流入小计                                  2,558,700,000.00             1,350,000,000.00

     偿还债务支付的现金                               1,150,000,000.00               900,000,000.00

     分配股利、利润或偿付利息支付
                                                       209,115,662.94                157,675,120.21
的现金

     支付其他与筹资活动有关的现金                      188,593,470.40                175,641,024.00

筹资活动现金流出小计                                  1,547,709,133.34             1,233,316,144.21

筹资活动产生的现金流量净额                            1,010,990,866.66               116,683,855.79

四、汇率变动对现金及现金等价物的
影响

五、现金及现金等价物净增加额                           269,419,694.65                -59,153,093.37

     加:期初现金及现金等价物余额                      361,215,412.05                261,982,833.79

六、期末现金及现金等价物余额                           630,635,106.70                202,829,740.42


法定代表人:朱吉满                  主管会计工作负责人:刁秀强             会计机构负责人:纪作哲


二、审计报告

第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。


                                                                         哈尔滨誉衡药业股份有限公司
                                                                                 法定代表人:朱吉满
                                                                             二〇一七年十月二十八日




                                                第 27 页